SIRT1 Activation Attenuates Bone Cancer Pain by Inhibiting mGluR1/5

Area of Science:

• Neuroscience
• Oncology
• Pharmacology

Background:

• Bone cancer pain (BCP) is a significant clinical challenge with poorly understood mechanisms.
• Sirtuin 1 (SIRT1) is implicated in pain modulation, but its role in BCP is unclear.
• Previous studies suggest SIRT1 activation may attenuate BCP, but its expression and activity in BCP models are unknown.

Purpose of the Study:

• To investigate the time course of SIRT1 expression and activity in the spinal cord during BCP development.
• To determine if SRT1720, a SIRT1 activator, alleviates BCP by inhibiting metabotropic glutamatergic receptor (mGluR) 1/5.
• To examine the effect of downregulating spinal SIRT1 on pain behavior and mGluR1/5 expression.

Main Methods:

• Mice with BCP were analyzed for SIRT1 expression (protein, mRNA, activity) and pain behaviors.
• SRT1720 was administered intrathecally to tumor-bearing mice to assess its analgesic effects and impact on mGluR1/5.
• Adeno-associated virus carrying SIRT1 short hairpin RNA (AAV-SIRT1-shRNA) was used to downregulate spinal SIRT1 in normal mice.

Main Results:

• BCP mice exhibited mechanical allodynia, spontaneous flinching, and decreased spinal SIRT1 levels.
• SRT1720 treatment reduced pain behaviors and decreased spinal mGluR1/5 expression in tumor-bearing mice.
• AAV-SIRT1-shRNA administration induced pain behaviors and increased spinal mGluR1/5 expression in normal mice.

Conclusions:

• SIRT1 plays a critical role in the development and maintenance of bone cancer pain.
• SRT1720 alleviates BCP in mice by activating spinal SIRT1, which inhibits mGluR1/5 expression.
• Targeting SIRT1 represents a potential therapeutic strategy for managing bone cancer pain.